Dihexa vs Omberacetam (Noopept)
Noopept has limited human patient studies; Dihexa is preclinical with an FDA human-data gap and a key retracted mechanistic paper. This is an evidence-maturity comparison, not a recommendation.
| Attribute | Dihexa | Omberacetam (Noopept) |
|---|---|---|
| Human evidence | FDA states it has not identified human exposure data for drug products containing dihexa acetate by any route. | Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified. |
| Research focus | Experimental cognition, synaptogenesis, neurodegeneration research | Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic |
| Regulatory status | Not an approved medicine. FDA lists dihexa acetate among bulk substances with significant safety-information gaps; a UNII/GSRS identity record does not imply approval. | FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally. |
| Route / formulation | No route has an established human therapeutic safety/dose framework for dihexa itself. | Most clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols. |
Why these are compared
These compounds appear in the brain & cognitive performance evidence landscape, but they are not interchangeable. Dihexa is angiotensin-iv-derived peptidomimetic small molecule studied in experimental cognition, synaptogenesis, neurodegeneration research; Omberacetam (Noopept) is synthetic peptidomimetic / dipeptide-derived small molecule studied in post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Dihexa: No identified human drug exposure; preclinical evidence with major research-integrity warning.
Omberacetam (Noopept): Limited older human clinical evidence; healthy cognitive enhancement unestablished.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head trial; Dihexa lacks identified human exposure data. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.